

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM391801

| | | | |
|------------------------------|--------------------------------|-----------------------|-----------------------|
| SUBMISSION TYPE: | RESUBMISSION | | |
| NATURE OF CONVEYANCE: | RELEASE OF SECURITY INTEREST | | |
| RESUBMIT DOCUMENT ID: | 900368538 | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| MIDCAP FINANCIAL TRUST | FORMERLY MIDCAP FUNDING V, LLC | 06/20/2016 | Corporation: DELAWARE |
| RECEIVING PARTY DATA | | | |
| Name: | CARDIOME PHARMA CORP. | | |
| Street Address: | c/o 1441 Creekside Drive | | |
| Internal Address: | Suite 600, 6th Floor | | |
| City: | Vancouver, BC | | |
| State/Country: | CANADA | | |
| Postal Code: | V6J 4S7 | | |
| Entity Type: | Corporation: CANADA | | |
| Name: | CARDIOME, INC. | | |
| Street Address: | c/o 1441 Creekside Drive | | |
| Internal Address: | Suite 600, 6th Floor | | |
| City: | Vancouver, BC | | |
| State/Country: | CANADA | | |
| Postal Code: | V6J 4S7 | | |
| Entity Type: | Corporation: DELAWARE | | |
| Name: | ARTESIAN THERAPEUTICS, INC. | | |
| Street Address: | c/o 1441 Creekside Drive | | |
| Internal Address: | Suite 600, 6th Floor | | |
| City: | Vancouver, BC | | |
| State/Country: | CANADA | | |
| Postal Code: | V6J 4S7 | | |
| Entity Type: | Corporation: DELAWARE | | |
| Name: | MURK ACQUISITION SUB, INC. | | |
| Street Address: | c/o 1441 Creekside Drive | | |
| Internal Address: | Suite 600, 6th Floor | | |
| City: | Vancouver, BC | | |
| State/Country: | CANADA | | |
| Postal Code: | V6J 4S7 | | |

TRADEMARK

| | |
|--------------------------|---|
| Entity Type: | Corporation: DELAWARE |
| Name: | CORREVIO LLC |
| Street Address: | c/o 1441 Creekside Drive |
| Internal Address: | Suite 600, 6th Floor |
| City: | Vancouver, BC |
| State/Country: | CANADA |
| Postal Code: | V6J 4S7 |
| Entity Type: | Limited Liability Company: DELAWARE |
| Name: | CARDIOME INTERNATIONAL AG |
| Street Address: | c/o 1441 Creekside Drive |
| Internal Address: | Suite 600, 6th Floor |
| City: | Vancouver, BC |
| State/Country: | CANADA |
| Postal Code: | V6J 4S7 |
| Entity Type: | Aktiengesellschaft (Ag): SWITZERLAND |
| Name: | CORREVIO INTERNATIONAL SARL |
| Street Address: | c/o 1441 Creekside Drive |
| Internal Address: | Suite 600, 6th Floor |
| City: | Vancouver, BC |
| State/Country: | CANADA |
| Postal Code: | V6J 4S7 |
| Entity Type: | SOCIÉTÉ À RESPONSABILITÉ LIMITÉE: SWITZERLAND |
| Name: | CORREVIO (UK) LTD. |
| Street Address: | c/o 1441 Creekside Drive |
| Internal Address: | Suite 600, 6th Floor |
| City: | Vancouver, BC |
| State/Country: | CANADA |
| Postal Code: | V6J 4S7 |
| Entity Type: | Private Limited Company: UNITED KINGDOM |
| Name: | CARDIOME UK LIMITED |
| Street Address: | c/o 1441 Creekside Drive |
| Internal Address: | Suite 600, 6th Floor |
| City: | Vancouver, BC |
| State/Country: | CANADA |
| Postal Code: | V6J 4S7 |
| Entity Type: | Private Limited Company: UNITED KINGDOM |
| Name: | CORREVIO (AUSTRALIA) PTY LTD. |
| Street Address: | c/o 1441 Creekside Drive |
| Internal Address: | Suite 600, 6th Floor |

TRADEMARK

REEL: 005839 FRAME: 0412

| | |
|-----------------------|--|
| City: | Vancouver, BC |
| State/Country: | CANADA |
| Postal Code: | V6J 4S7 |
| Entity Type: | Proprietary Limited Company: AUSTRALIA |

PROPERTY NUMBERS Total: 11

| Property Type | Number | Word Mark |
|----------------------|----------|-----------|
| Registration Number: | 3244293 | CARDIOME |
| Registration Number: | 3244294 | |
| Registration Number: | 3282759 | CARDIOME |
| Registration Number: | 3282761 | |
| Registration Number: | 4366123 | CORREVIO |
| Registration Number: | 4366122 | |
| Registration Number: | 4373761 | CORREVIO |
| Registration Number: | 4451751 | CORREVIO |
| Registration Number: | 4451764 | CORREVIO |
| Registration Number: | 4451793 | |
| Serial Number: | 85712167 | CARDIOME |

CORRESPONDENCE DATA

Fax Number: 2127352000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-735-2811

Email: mribando@skadden.com

Correspondent Name: Skadden, Arps, Slate, Meagher & Flom

Address Line 1: Four Times Square

Address Line 2: Monique L. Ribando

Address Line 4: New York, NEW YORK 10036

| | |
|--------------------------------|-------------------|
| ATTORNEY DOCKET NUMBER: | 122920/8 |
| NAME OF SUBMITTER: | Naomi R. Sosner |
| SIGNATURE: | /Naomi R. Sosner/ |
| DATE SIGNED: | 07/18/2016 |

Total Attachments: 15

source=Cardiome_Midcap_IP_Security_Release#page1.tif

source=Cardiome_Midcap_IP_Security_Release#page2.tif

source=Cardiome_Midcap_IP_Security_Release#page3.tif

source=Cardiome_Midcap_IP_Security_Release#page4.tif

source=Cardiome_Midcap_IP_Security_Release#page5.tif

source=Cardiome_Midcap_IP_Security_Release#page6.tif

source=Cardiome_Midcap_IP_Security_Release#page7.tif

source=Cardiome_Midcap_IP_Security_Release#page8.tif

source=Cardiome_Midcap_IP_Security_Release#page9.tif
source=Cardiome_Midcap_IP_Security_Release#page10.tif
source=Cardiome_Midcap_IP_Security_Release#page11.tif
source=Cardiome_Midcap_IP_Security_Release#page12.tif
source=Cardiome_Midcap_IP_Security_Release#page13.tif
source=CoverSheet#page1.tif
source=Notice#page1.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this “**Release**”), dated as of June 20, 2016, is made by and between MIDCAP FINANCIAL TRUST as successor-in-interest to MIDCAP FUNDING V, LLC (“**Agent**”), and CARDIOME PHARMA CORP. (the “**Canadian Assignor**”), CARDIOME, INC. (“**Cardiome, Inc.**”), ARTESIAN THERAPEUTICS, INC. (“**Artesian**”), MURK ACQUISITION SUB, INC. (“**Murk**”), CORREVIO LLC (“**Correvio LLC**” and, together with Cardiome, Inc., Artesian and Murk, (the “**U.S. Assignees**”), CARDIOME INTERNATIONAL AG (“**Cardiome AG**”), CORREVIO INTERNATIONAL SARL (“**Cardiome Sarl**” and, together with Cardiome AG, the “**Swiss Assignees**”), CORREVIO (UK) LTD. (“**Correvio (UK)**”), CARDIOME UK LIMITED (“**Cardiome UK**” and, together with Correvio (UK), the “**UK Assignees**”) and CORREVIO (AUSTRALIA) PTY LTD. (“**Correvio (Australia)**” and, together with the Swiss Assignees, the Canadian Assigness and the UK Assignee, the “**Foreign Assignees**” and the Foreign Assignees together with the U.S. Assignees, each an “**Assignee**” and collectively the “**Assignees**”).

W I T N E S S E T H:

WHEREAS, the Assignees and the Assignor are parties to (i) that certain Credit, Security and Guaranty Agreement by and between Agent, the Lenders and the Assignees, dated as of July 18, 2014 (as the same may be amended, modified or supplemented from time to time, the “**Credit Agreement**”; capitalized terms used herein are used as defined in the Credit Agreement) and (ii) that certain Intellectual Property Security Agreement, dated as of July 18, 2014 (the “**Intellectual Property Security Agreement**”);

WHEREAS, pursuant to the terms of the Credit Agreement and the other Financing Documents, each Assignee has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of the Assignee’s right, title and interest, whether then existing or thereafter acquired, in, to and under all of the Collateral (including the Copyrights, Trademarks, Patents, and Mask Works);

WHEREAS, pursuant to the Intellectual Property Security Agreement, to secure its Obligations under the Credit Agreement and the other Financing Documents, (i) each U.S. Assignee granted and pledged to Agent, for the ratable benefit of the Lenders, a security interest in all of each U.S. Assignee’s right, title and interest in, to and under its intellectual property (the “**U.S. Assignee Intellectual Property**”) and (ii) each of the Foreign Assignees granted and pledged to Agent, for the ratable benefit of the Lenders, a security interest in all of such Foreign Assignee’s right, title and interest in, to and under its intellectual property located in the United States (the “**Foreign Assignee Intellectual Property**”, and together with the U.S. Assignee Intellectual Property, the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) (i) With regard to each U.S. Assignee, any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also

constitutes a trade secret, whether then or thereafter existing, created, acquired or held, including, without limitation, those set forth on Exhibit A attached hereto (the “**U.S. Assignee Copyrights**”) and (ii) with regard to each Foreign Assignee, any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof located in the United States, whether published or unpublished and whether or not the same also constitutes a trade secret, then or thereafter existing, created, acquired or held, including, without limitation, those set forth on Exhibit A attached hereto (the “**Foreign Assignee Copyrights**” and together with the U.S. Assignee Copyrights, collectively, the “**Copyrights**”);

(b) (i) With regard to each U.S. Assignee, any and all trade secrets, and any and all intellectual property rights in computer software and computer software products then or thereafter existing, created, acquired or held and (ii) with regard to each Foreign Assignee, any and all trade secrets, and any and all intellectual property rights in computer software and computer software products then or thereafter existing, created, acquired or held in the United States;

(c) (i) With regard to each U.S. Assignee, any and all design rights that may be available to such U.S. Assignee then or thereafter existing, created, acquired or held and (ii) with regard to each Foreign Assignee, any and all design rights that may be available to such Foreign Assignee then or thereafter existing, created, acquired or held in the United States;

(d) (i) With regard to each U.S. Assignee, all patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (the “**U.S. Assignee Patents**”) and (ii) with regard to each Foreign Assignee, all patents, patent applications and like protections located in the United States, including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (the “**Foreign Assignee Patents**” and together with the U.S. Assignee Patents, collectively, the “**Patents**”);

(e) (i) With regard to each U.S. Assignee, any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such U.S. Assignee connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (the “**U.S. Assignee Trademarks**”) and (ii) with regard to each Foreign Assignee, any trademark and servicemark rights located in the United States, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Foreign Assignee connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (the “**Foreign Assignee Trademarks**” and together with the U.S. Assignee Trademarks, collectively, the “**Trademarks**”);

(f) (i) With regard to each U.S. Assignee, all mask works or similar rights available for the protection of semiconductor chips, then owned or thereafter acquired, including without limitation those set forth on Exhibit D attached hereto (the “**U.S. Assignee Mask Works**”) and (ii) with regard to each Foreign Assignee, all mask works or similar rights available for the protection of semiconductor chips, then owned or thereafter acquired in the United States, including, without limitation those set forth on Exhibit D attached hereto (the “**Foreign Assignee Mask Works**” and together with the U.S. Assignee Mask Works, collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) (i) With regard to each U.S. Assignee, all licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights and (ii) with regard to each Foreign Assignee, all licenses or other rights to use any of the Copyright, Patents, Trademarks, or Mask Works in the United States and all license fees and royalties arising in the United States from such use to the extent permitted by such licenses or rights;

(i) All amendments, extensions, renewals and extensions of any of the foregoing Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

WHEREAS, the Intellectual Property Security Agreement was recorded with the United States Patent and Trademark Office on July 24, 2014 at Reel/Frame No. 005329/0068;

WHEREAS, the Assignees fully satisfied their Obligations under the Credit Agreement and the other Financing Documents on June 14, 2016; and

WHEREAS, the Assignees desire that the Assignor terminate and release its security interest in and to the Intellectual Property Collateral.

NOW THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, the Assignor agrees as follows:

SECTION 1. Defined Terms. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Intellectual Property Security Agreement or the Credit Agreement, as applicable.

SECTION 2. Termination and Release. The Assignor hereby terminates, releases and discharges fully, without representation, warranty or recourse of any kind, its

continuing security interest in all of each Assignee's right, title, and interest in and to the Intellectual Property Collateral, including the Copyrights set forth on Exhibit A attached hereto, the Patents set forth on Exhibit B attached hereto, the Trademarks set forth on Exhibit C attached hereto and the Mask Works set forth on Exhibit D attached hereto, and reassigns and transfers to the Assignees any right, title and interest that the Assignor may have in the Intellectual Property Collateral.

SECTION 3. Recordation. The Assignor hereby authorizes the Assignees, or the Assignees' authorized representative, to record this Release with the United States Patent and Trademark Office.

SECTION 4. Further Assurances. The Assignor hereby agrees to duly execute and deliver to the Assignees any further documents and to do such other acts that the Assignees (or their respective agents or designees) reasonably request, at the Assignees' sole cost and expense, in order to confirm this Release and the Assignees' right, title and interest in the Intellectual Property Collateral.

SECTION 5. Governing Law. THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

ASSIGNEES:


CARDIOME PHARMA CORP.

By:   (SEAL)

Name: David D. McMasters / Jennifer Archibald

Title: Director / Director

CARDIOME, INC.

By:  (SEAL)

Name: Jennifer Archibald

Title: Director



ARTESIAN THERAPEUTICS, INC.

By:  (SEAL)

Name: Jennifer Archibald

Title: Director



MURK ACQUISITION SUB, INC.

By:   (SEAL)

Name: David D. McMasters / Jennifer Archibald

Title: Director / Director



CORREVIO LLC

By:   (SEAL)

Name: David D. McMasters / Jennifer Archibald

Title: Authorized Signatory / Chief Financial Officer



CARDIOME INTERNATIONAL AG

By:   (SEAL)

Name: David D. McMasters / Jennifer Archibald

Title: Director / Director



CORREVIO (UK) LTD.

By:   (SEAL)

Name: David D. McMasters / Jennifer Archibald

Title: Director / Director



CORREVIO INTERNATIONAL SARL

By:   (SEAL)

Name: David D. McMasters / Jennifer Archibald

Title: Director / Director

CORREVIO (AUSTRALIA) PTY LTD.

By:   (SEAL)

Name: David D. McMasters / Jennifer Archibald

Title: Director / Director

CARDIOME UK LIMITED

By:  (SEAL)

Name: Jennifer Archibald


Title: Director

AGENT:

MIDCAP FINANCIAL TRUST,
as Agent for Lenders

By: Apollo Capital Management, L.P.,
its investment manager

By: Apollo Capital Management GP, LLC,
its general partner

By:  (SEAL)

Name: Maurice Amsellem

Title: Authorized Signatory

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

| Registered Owner | Patent | Name / Identifier of IP or License | Type of IP (e.g., patent, TM, ©, mask work) or License Agreement | Expiration Date (if a License, expiration of License and Licensed Property) |
|-------------------------|---------------|---|---|--|
| Cardiome Pharma Corp.** | Brinavess | United States - 7,101,877 | Patent | 3/31/2019 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,057,053 | Patent | 10/16/2020 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,259,184 | Patent | 10/06/2020 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,524,879 | Patent | 10/06/2020 |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,008,342 | Patent | 10/06/2020 |
| Cardiome Pharma Corp.** | Brinavess | United States - 14/081,792 | Patent | -- |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,534,790 | Patent | 3/31/2019 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,875,611 | Patent | 3/31/2019 |
| Cardiome Pharma Corp. | Other | United States - 7,687,536 | Patent | 08/03/2020 |
| Cardiome Pharma Corp. | Other | United States - 7,053,087 | Patent | 03/03/2020 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,767,830 | Patent | 03/31/2019 |
| Cardiome Pharma | Brinavess | United States – 8,163,938 | Patent | 10/31/2023 |

| | | | | |
|-------------------------------|-----------|-------------------------------|--------|------------|
| Corp.** | | | | |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,345,087 | Patent | 10/16/2020 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,786,119 | Patent | 11/18/2025 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,977,373 | Patent | 01/08/2027 |
| Cardiome Pharma Corp.** | Brinavess | United States - 13/612,559 | Patent | -- |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,692,002 | Patent | 06/04/2028 |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,058,304 | Patent | 05/13/2027 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,754,897 | Patent | 06/17/2028 |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,022,098 | Patent | 10/16/2020 |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,080,673 | Patent | 06/15/2026 |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,344,162 | Patent | 06/15/2026 |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,618,311 | Patent | 06/15/2026 |
| Cardiome Pharma Corp. | Other | United States - 7,105,534 | Patent | 06/12/2021 |
| Cardiome Pharma Corp.** | Brinavess | United States - 12/114,652 | Patent | -- |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,263,638 | Patent | 03/16/2026 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,345,086 | Patent | 09/20/2025 |

MidCap / Cardiome / U.S. IP Security Agreement

| | | | | |
|---------------------------|-----------|----------------------------|--------|------------|
| Cardiome Pharma Corp.** | Brinavess | United States - 7,820,712 | Patent | 09/19/2025 |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,188,140 | Patent | 5/03/2024 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,674,820 | Patent | 07/08/2027 |
| Cardiome Pharma Corp.** | Brinavess | United States - 8,207,219 | Patent | 8/09/2024 |
| Cardiome Pharma Corp.** | Brinavess | United States - 7,507,545 | Patent | 05/22/2022 |
| Cardiome International AG | Brinavess | United States - 13/817,274 | Patent | -- |
| Correvio LLC* | Aggrastat | United States - 61/838,742 | Patent | -- |
| Correvio LLC* | Aggrastat | United States - 61/838,731 | Patent | -- |
| Correvio LLC* | Aggrastat | United States - 61/838,734 | Patent | -- |
| Correvio LLC* | Aggrastat | United States - 61/942,577 | Patent | -- |
| Correvio LLC* | Aggrastat | United States - 13/130,340 | Patent | -- |

EXHIBIT C

Trademarks

| Registered Owner | Mark | Name / Identifier of IP or License | Type of IP (e.g., patent, TM, ©, mask work) or License Agreement | Expiration Date (if a License, expiration of License and Licensed Property) |
|-------------------------|--|---|---|--|
| Cardiome Pharma Corp. | CARDIOME | United States - 3244293 | TM | 11/26/2019 |
| Cardiome Pharma Corp. | CARDIOME PHARMA CORP.. Logo | United States - 3244294 | TM | 05/26/2020 |
| Cardiome Pharma Corp. | CARDIOME | United States - 3282759 | TM | 05/25/2019 |
| Cardiome Pharma Corp. | CARDIOME PHARMA CORP.. Logo | United States - 3282761 | TM | 09/01/2020 |
| Correvio LLC* | CORREVIO & Heart Design with 2 curves/3 curves | United States - 4366123 | TM | 06/08/2014 |
| Correvio LLC* | Heart Design with 2 curves/3 curves | United States - 4366122 | TM | 06/29/2019 |
| Correvio LLC* | CORREVIO | United States - 4373761 | TM | 03/25/2016 |
| Correvio LLC* | CORREVIO | United States - 4451751 | TM | 01/02/2021 |
| Correvio LLC* | CORREVIO & Heart Design with 2 curves/3 curves | United States - 4451764 | TM | 11/15/2019 |
| CorrevioLLC | Heart Design with 2 curves/3 curves | United States - 4451793 | TM | 10/08/2019 |
| Cardiome Pharma Corp. | CARDIOME | United States - 85/712167 | TM | 06/17/2019 |

EXHIBIT D

Mask Works

None.

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM388574

| | | | |
|------------------------------|------------------------------|-----------------------|---------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | RELEASE OF SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| MIDCAP FINANCIAL TRUST | | 06/20/2016 | Statutory Trust: DELAWARE |
| RECEIVING PARTY DATA | | | |
| Name: | CARDIOME PHARMA CORP. | | |
| Street Address: | c/o 1441 Creekside Drive | | |
| Internal Address: | Suite 600, 6th Floor | | |
| City: | Vancouver, BC | | |
| State/Country: | CANADA | | |
| Postal Code: | V6J 4S7 | | |
| Entity Type: | Corporation: CANADA | | |
| Name: | CARDIOME, INC. | | |
| Street Address: | c/o 1441 Creekside Drive | | |
| Internal Address: | Suite 600, 6th Floor | | |
| City: | Vancouver, BC | | |
| State/Country: | CANADA | | |
| Postal Code: | V6J 4S7 | | |
| Entity Type: | Corporation: DELAWARE | | |
| Name: | ARTESIAN THERAPEUTICS, INC. | | |
| Street Address: | c/o 1441 Creekside Drive | | |
| Internal Address: | Suite 600, 6th Floor | | |
| City: | Vancouver, BC | | |
| State/Country: | CANADA | | |
| Postal Code: | V6J 4S7 | | |
| Entity Type: | Corporation: DELAWARE | | |
| Name: | MURK ACQUISITION SUB, INC. | | |
| Street Address: | c/o 1441 Creekside Drive | | |
| Internal Address: | Suite 600, 6th Floor | | |
| City: | Vancouver, BC | | |
| State/Country: | CANADA | | |
| Postal Code: | V6J 4S7 | | |
| Entity Type: | Corporation: DELAWARE | | |

TRADEMARK

REEL: 005839 FRAME: 0428

CH \$290.00 3244293



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

July 11, 2016

PTAS

SKADDEN, ARPS, SLATE, MEAGHER & FLOM
FOUR TIMES SQUARE
MONIQUE L. RIBANDO
NEW YORK, NY 10036



900368538

United States Patent and Trademark Office
Notice of Non-Recordation of an Assignment Document

The enclosed document has been examined and found non-recordable by the Assignment Recordation Branch of the U.S. Patent and Trademark Office. The reason(s) for non-recordation are stated below:

1. The cover sheet submitted for recording is not acceptable. The conveying party's name(s) on cover sheet is inconsistent with the supporting document.

Documents being resubmitted for recordation must reflect the corrected information to be recorded, the Document ID number referenced above and all pages from this submitted document. The original date of filing of this assignment document will be maintained if resubmitted with the appropriate correction(s) by **Wednesday, August 10, 2016**, as outlined under 37 CFR 3.51. The resubmitted document must include a stamp with the official date of receipt under 37 CFR 3. Applicants may use the certified procedures under 37 CFR 2.197 or 2.198 for resubmission of the returned papers if they desire to have the benefit of the date of deposit in the United States Postal Service.

To file the resubmission electronically, navigate to the ETAS website at <http://etas.uspto.gov>, click the Start Resubmission button and enter the following information:

Document ID: 900368538

Access Code: 8W9IH04YN0U3TAO

To file the resubmission in paper, send documents to: U.S. Patent and Trademark Office, Mail Stop: Assignment Recordation Branch, P.O. BOX 1450, Alexandria, VA 22313. If you have any questions regarding this notice, you may contact the Assignment Recordation Branch at 571-272-3350.

LANAI BUTLER
ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION